← Back to headlines
Bristol-Myers Squibb Faces Mixed Analyst Sentiment Despite Industry Momentum
Pharmaceutical giant Bristol-Myers Squibb (BMY) is experiencing mixed analyst sentiment regarding its stock performance, even as the broader healthcare industry shows strong momentum.
28 Mar, 20:51 — 28 Mar, 20:51
Sources
Showing 1 of 1 sources
